title: Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.
abstract: The growing number of disease-modifying treatments (DMTs) for patients with multiple sclerosis (MS) and the high acquisition costs of these DMTs are likely to increase the demand for information on their cost effectiveness. To improve the comparability and applicability of the findings from future cost-effectiveness analyses, it would be useful to have a clear understanding of the methodological challenges of modelling the cost effectiveness of DMTs in MS and the different approaches taken by such studies to date. In contrast to previous review studies, this review focuses on long-term time horizon (≥10 years) simulation-based cost-effectiveness analyses with homogeneous contexts of analysis (i.e. those with similar study objectives, comparators, and target populations) published over the past decade. By doing so, it provides a clearer picture of how modelling approaches taken in the existing studies truly differ across studies, and reveals major areas for improvement in conducting future cost-effectiveness analyses of DMTs for patients with MS.
authors.affiliation: Evidera, 430 Bedford St., Suite 300, Lexington, MA, 02420, USA, shien.guo@evidera.com.
authors.forename: Shien
authors.initials: S
authors.lastname: Guo
authors.forename: Christopher
authors.initials: C
authors.lastname: Pelligra
authors.forename: Catherine
authors.initials: C
authors.lastname: Saint-Laurent Thibault
authors.forename: Luis
authors.initials: L
authors.lastname: Hernandez
authors.forename: Anuraag
authors.initials: A
authors.lastname: Kansal
mesh_terms: D000276:Adjuvants, Immunologic / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D018803:Models, Economic; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics*
chemical_list: D000276:Adjuvants, Immunologic; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents